id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-266313-b518n9dx	Cao, Yu-chen	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence	2020-04-02		.txt	text/plain	5542	262	48	China has also taken immediate action to put remdesivir into clinical trials with the purpose of applying it into clinical therapeutics for Corona Virus Disease 2019 (COVID-19). When we set our sights on the broad-spectrum antiviral drugs, we found that a drug unlisted, remdesivir, has demonstrated strength in trials related to MERS-CoV and Ebola virus infection. This article starts from the structure, immunogenicity, and pathogenesis of infection of the SARS-CoV-2, and then analyzes the feasibility of conducting trials and putting into clinical use of COVID-19 from the pharmacological characteristics and successful cases of remdesivir. Remdesivir (GS-5734) is a nucleoside analogues drug (Fig. 3B ) with extensive antiviral activity and effective treatment of lethal Ebola and Nipah virus infections in nonhuman primates [21] . The need of treatment on COVID-19 is urgent, so if the results of clinical trials prove it has the potential to benefit the treatment, according to China's "Compassionate Use", remdesivir will be more immediately used in patients with severe illness.	./cache/cord-266313-b518n9dx.txt	./txt/cord-266313-b518n9dx.txt